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A key role of both coagulation and vascular thrombosis has been reported since
the first descriptions of multiple sclerosis (MS). Subsequently, the observation of a
close concordance between perivascular fibrin(ogen) deposition and the occurrence
of clinical signs in experimental allergic encephalomyelitis (EAE), an animal model of
MS, led to numerous investigations focused on the role of thrombin and fibrin(ogen).
Indeed, the activation of microglia, resident innate immune cells, occurs early after
fibrinogen leakage in the pre-demyelinating lesion stage of EAE and MS. Thrombin
has both neuroprotective and pro-apoptotic effects according to its concentration.
After exposure to high concentrations of thrombin, astrocytes become reactive and
lose their neuroprotective and supportive functions, microglia proliferate, and produce
reactive oxygen species, IL-1β, and TNFα. Heparin inhibits the thrombin generation
and suppresses EAE. Platelets play an important role too. Indeed, in the acute phase
of the disease, they begin the inflammatory response in the central nervous system
by producing of IL-1alpha and triggering and amplifying the immune response. Their
depletion, on the contrary, ameliorates the course of EAE. Finally, it has been proven that
the use of several anticoagulant agents can successfully improve EAE. Altogether, these
studies highlight the role of the coagulation pathway in the pathophysiology of MS and
suggest possible therapeutic targets that may complement existing treatments.
Keywords: coagulation, neuroinflammation, multiple sclerosis, neuromyelitis optica spectrum disorders,
thrombosis
INTRODUCTION
Multiple sclerosis (MS) is an inflammatory demyelinating and degenerative disease of the central
nervous system (CNS) characterized by neuroinflammation and neurodegeneration and affecting
prevalently women (1). Most commonly, MS begins with a relapsing–remitting course with
alternation of clinical relapses and remissions (2). With time, most of these cases switch to a
secondary progressive phase with steady accumulation of disability. In a lower percentage of
patients (about 20%) the disease is progressive from the beginning and is defined as primarily
progressive form. Experimental autoimmune encephalomyelitis (EAE) is the most studied animal
model of MS (3). It is possible to induce EAE in mice by immunization with spinal cord
homogenates or by passive transfer of sensitized T cells.
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Several recent studies have highlighted the importance of
the interplay between the activation of the coagulation cascade
and neuroinflammation, suggesting that coagulation factors are
crucial not only for the activation of the acute hemostatic
cascade, but have a broader role involving neurodegeneration
and neuroinflammation (4–20).
We will review this evidence, trying to offer an
overview of possible targets that may complement existing
immunomodulatory therapeutic tools.
HISTORY
The role of vascular thrombosis due to increased coagulation
in MS has been taken into consideration since its first
description based on histopathological observations. In 1882,
Ribbert postulated that MS lesion could be consequent to central
vascular thrombosis due to bloodstream infection (21). This
hypothesis was supported by Pierre Marie, who thought that
infections have a causative role in MS through the induction
of brain vascular damage and thrombosis (21). Thereafter in
1930–40s, Tracy Putnam pointed out venular thrombosis as
the primary MS cause based on histologic and experimental
observations (22). He observed thrombi in acute lesions with
small plaques surrounding the engorged veins. He occasionally
observed thrombi also in other body organs of MS patients.
Moreover, Putnam found that most MS patients had a peculiar
defect of the clotting mechanism, suggesting that thrombosis was
not consequent to the vessel wall injury but to blood alterations
such as an increase in fibrinogen.
The first studies on serum coagulation factors were conducted
in small MS patient cohorts and led to conflicting results.
The clotting time was found shortened (23), normal (24) or
prolonged (25). There was disagreement also regarding the
prothrombin time since it was similarly reported either shortened
(26), prolonged, (27, 28) or normal (25, 29). Putnam (30) and
Persson (31) showed an increase of fibrinogen especially during
the exacerbations while other studies found it to be normal in 9
patients in active clinical progression except one (25) as well as in
33MS patients except two patients with increased fibrinogen, of
which one examined during a relapse (32).
Furthermore, thrombocytes were studied in MS with
divergent results. One study reported a short clot retraction
time during acute disease exacerbation (33), whereas it was
found to be normal or prolonged in other works (25, 32). An
elevated platelet adhesiveness and a short clot retraction time was
found mainly during acute disease exacerbation (33). Fog et al.
found the reduction in thrombocyte count during the disease
exacerbation and its increase during the clinical improvement
(34) whereas other authors found thrombocyte count normal
in MS patients (24, 29, 32) or reduced in several patients in
phase of disease remission (32). Persson found an increase in
adhesive platelets in the prodromal phase of thrombosis, which
rapidly decreased during the thrombi formation (35). Similarly,
Wright et al demonstrated increased adhesiveness of platelets
in acute and severe cases compared to controls suffering from
other neurological disorders and reporting normal values of
platelet adhesiveness (36). However, the possibility that steroid
therapy could influence this adhesiveness was not excluded.
Another explanation for the negative results related to platelet
adhesiveness in MS patients found by Field and Caspary could be
presence of edetic acid (EDTA) in the test tubes which is known
to reduce platelet adhesiveness (37).
Interestingly, Putnam treated his MS patients with Dicumarol
in the 1940s and concluded that only patients with acute relapses
benefited from this therapy (21). All in all, the enthusiasm for
anticoagulant therapy in the scientific community waned in the
following years because of its doubtful effectiveness (21).
At the same time, in the 1930s the pathological MS research
radically changed its own course after the development of
EAE, a prototypic model of MS, through the immunization
of susceptible animals with CNS components. Since then,
the majority of the studies on disease pathophysiology
focused on immunological mechanisms (38). While the
results of genome-wide association studies (GWAS) (39)
and the success of treatments based on immunological
targets reinforce this hypothesis, other studies still
suggest a key role for a dysfunction of coagulation,
possibly linked to the ongoing inflammation, in CNS
autoimmunity (9–11, 15, 40–42).
COAGULATION CASCADE SUMMARY
Coagulation is a complex process involving blood changes
that lead to the formation of a blood clot (43). It is
classically aimed to ensure haemostasis, an important biological
process that contrasts bleeding after vessel injury. However,
coagulation is activated not only by direct vascular injury but
also by functional injury due to hypoxia, sepsis, malignancy,
inflammation, etc (44, 45). A pathological imbalance of
haemostasis may lead to intravascular thrombosis despite the
coagulation process is controlled by several inhibitors limiting
the clot formation. However, in certain conditions thrombosis
is a physiological process called “immunothrombosis” involving
an intrinsic effector mechanism of innate immunity (46).
Immunothrombosis is specifically activated by either blood-
borne pathogens or circulating altered-self components on a
local platform consisting of fibrin, monocytes, neutrophils,
and platelets contributing to pathogen recognition. Innate
immune cells such as monocytes, neutrophils, dendritic cells
participate actively in this process propagating fibrin formation
and triggering platelet activation. This process contrasts either
tissue invasion, dissemination, or survival of pathogens. The
delimitation of immunothrombosis to only a restricted number
of microvessels likely ensures a sufficient overall organ perfusion.
Briefly, two traditional coagulation cascade pathways, so-
called intrinsic, and extrinsic, lead to the same final common
pathway of factor X and thrombin ending with fibrin formation.
These coagulation pathways are a series of reactions converting
the inactive precursors to active ones in order to catalyze the next
reaction in the cascade. Majority of clotting factors are precursors
of proteolytic enzymes known as zymogens that circulate in an
inactive form.
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Platelets exert potent procoagulant functions via the calcium-
dependent cell-surface exposure of phospholipids such as
phosphatidylserine, which act as cofactors for the proteolytic
reactions triggered by coagulation factors. Coagulation process,
in turn, fosters platelet activation and accumulation, mainly
through the protease thrombin, which promotes platelet
activation by both cleavage and activation of platelet’s proteinase-
activated receptors (PAR). Platelets early aggregate to form a
“platelet plug” to close provisionally the vessel wall injury. This
platelet adhesion to subendothelial surface is reinforced by von
Willebrand factor (vWF), which is a glycoprotein present in
blood plasma and produced in endothelium, megakaryocytes,
and subendothelial connective tissue. Activated platelets release
into the plasma the contents of their granules, which activate
other platelets.
In the extrinsic tissue factor (TF) pathway, after vessel damage
blood-based coagulation factor VII links with TF, which is
present in the subendothelial tissue and fibroblasts as well as in
a smaller quantity in circulating form on monocytes, to form an
activated complex TF-FVIIa. FVII is also activated by FXa, FIXa,
FXIIa and thrombin. Under some pathologic circumstances, TF
is expressed also by monocytes, neutrophils, endothelial cells,
and platelets with increased levels of circulating TF-positive
microparticles that amplify the process of coagulation cascade.
The activated complex TF-FVIIa activates coagulation factors
FIX and FX.
Intrinsic contact activation pathway, which mainly activates
thrombin, begins with formation of the primary complex
on exposed collagen by factor XII, high-molecular-weight
kininogen, prekallekerin, and factor XI. Endothelial collagen is
exposed only in course of endothelial damage. Factor XII convers
in active FXIIa that converts FXI into activated FXIa. FXIa further
activates factor IX, which acts with its cofactor FVIII to form
tenase complex on a phospholipid surface and to activate factor
X to FXa.
In common pathway FXa along with its cofactor FVa,
tissue phospholipids, platelet phospholipids and calcium forms
the prothrombinase complex, which activates prothrombin to
thrombin. Thrombin activates FV and FVIII, releasing the
latter from its link with vWF. Thrombin further cleaves
circulating fibrinogen to insoluble fibrin and activates factor
XIII, which covalently crosslinks fibrin polymers incorporated
in the platelet plug. This creates a fibrin network the building
block of a hemostatic plug. Thrombin has also pro-inflammatory
effects exciting the PAR present on monocytes, lymphocytes,
endothelium and dendritic cells. In addition, it is the most
important platelet activator activating FVIII and FV and their
inhibitor protein C in the presence of thrombomodulin (TM).
PLATELETS
Various studies have highlighted the contribution of blood
platelets to the inflammatory process that characterizes MS.
These cells may be involved also in the pathophysiology of other
neurological diseases, such as Alzheimer’s disease, Parkinson’s
disease and Huntington’s disease (47). The role of blood platelets
during the acute and chronic phase of inflammation is not
marginal. These cells release proinflammatory mediators, display
molecules on their surface with inflammatory functions and
interact with endothelial cells and leukocytes (48).
Platelets release several proinflammatory mediators. Three
types of secretory granules have been described in platelets: dense
granules, lysosomes, and alpha-granules (48). The latter type is
the most abundant. They are produced during megakaryocyte
maturation and are considered crucial for platelet functions.
Hundreds of soluble factors are stored in these alpha-granules,
including prothrombin, tissue factor, high molecular weight
kininogen, chemokines (RANTES, CXCL1, CXCL4, CXCL5,
CXCL7, CXCL8, CXCL12, CCL2, macrophage inflammatory
protein 1-alpha), proangiogenic and antiangiogenic proteins,
growth factors, and inhibitory proteases [e.g., plasminogen
activator inhibitor, alpha2-antiplasmin, antithrombin III (AT
III), protein S, protease nexin-2, plasminogen, and tissue factor
pathway inhibitor](48). Dense granules store ATP, GDP, ADP, 5-
HT, Ca, Mg and histamine, whereas lysosomal granules contain
glycohydrolases, and acid proteases (48). Interestingly, platelets
synthesize and secrete matrix metalloproteinases (MMPs)
as well as tissue inhibitors of MMPs (TIMPs). The main
MMP in platelets is MMP-1, which is important because
it activates protease activated receptor 1 (PAR-1), which, in
turn, is important for platelet aggregation (48). Through the
cyclooxygenase (COX) and platelet activating factor (PAF)
pathways, platelets are also able to synthesize lipid mediators,
including eicosanoids. PAF can also induce the production of
IL-1beta in platelets (48).
Platelets express many molecules on their surface that play
a role during the inflammatory response. P-selectin, which
translocates from the granules to the surface during the platelet
activation, can interact with leukocytes and endothelial cells
through the interaction with P-selectin glycoprotein-I (PSGL-
1). Platelets express also CD40L on their surface and release its
soluble form during activation. The latter, (49) together with
PAF (50) and MMPs (51), is crucial in order to increase the
permeabilization of the blood brain barrier (BBB).
Whether platelet activation is a primary event of MS
pathogenesis or it is secondary to endothelial injury is still
matter of debate (52). Platelets interact with leukocytes at the
endothelium of the BBB by releasing the adhesion molecule
PECAM-1 that triggers leukocyte infiltration (53). Moreover,
PAF disrupts endothelial BBB junctions and PAF receptors are
up-regulated in MS lesions (53).
Platelets are among the first cell types to begin the
inflammatory response in the CNS in the acute phase of MS
immune response and may be important to trigger and amplify it
by producing significant amounts of IL-1alpha (54).
Finally, activated platelets can produce large amounts of
Reactive Oxygen Species (ROS) and Reactive Nitrogen Species
(RNS) that can cause damage to proteins, lipids and nucleic
acids, leading to death of CNS cells. Importantly, CNS has
low antioxidant defenses and the composition of myelin seems
particularly vulnerable to ROS (55).
The importance of platelets in MS and in EAE has been
demonstrated also in experimental settings. Platelet depletion
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has been found to ameliorate the course of EAE (56). Moreover,
during EAE, platelets have been demonstrated to activate in
response to sialated glycolipids integrated into neuronal and
astroglial lipid rafts found within the BBB (57).
Starossom et al demonstrated that glatiramer acetate (GA),
a disease modifying treatment for MS, significantly inhibited
thrombin-induced activation of human and mouse platelets
(58). They showed that GA was able to inhibit calcium influx,
upregulation of CD62P and other markers of activation and
aggregation in human and mouse thrombin-activated platelets.
They also found that GA significantly reduced platelet-induced
upregulation of CD86 andMHC class II onmacrophages, leading
to a decreased platelet-mediated activation of macrophages.
THROMBIN
Thrombin is a 36-kDa serine protease, a key enzyme in the
coagulation cascade formed after cleavage of its precursor,
prothrombin (with a molecular weight of ∼72-kDa), by the
coagulation factor Xa (59). Prothrombin contains gamma-
carboxyglutamic acid, is synthesized in the liver and released
into bloodstream. It can be activated by vascular injury,
through limited proteolysis following upstream activation of the
coagulation cascade. Serum inhibitors and its own action regulate
the activity of thrombin.With its procoagulant and anticoagulant
functions, the role of thrombin is pivotal in thrombosis
and haemostasis. However thrombin has also hormone-like
properties that can influence many cells, including platelets,
lymphocytes, neurons and astrocytes (60).
Thrombin converts fibrinogen into fibrin and activates factor
XIII, affecting the cross-linking of fibrin monomers to produce a
stable fibrin clot. Thrombin’s function is peculiar as it has both
procoagulant and anticoagulant functions. The latter is mediated
through binding to TM, a receptor protein expressed on the
endothelial membranes, triggering a series of reactions that
lead to fibrinolysis. The endothelial protein C receptor (EPCR),
shed from the endothelial cells by inflammatory mediators and
thrombin, increases protein C activation by the thrombin-TM
complex, and inhibits leukocyte extravasation. Interestingly, TNF
alpha can down-regulate EPCR, and TM (61).
Depending on the concentrations, thrombin has been
demonstrated to have both neuroprotective and pro-apoptotic
effects (6, 62). At low to moderate concentrations, thrombin
is neuroprotective for hippocampal neurons and astrocytes
that lose their star morphology and maintain their supportive
role in the production of glutathione and in the reduction
of glutamate (7). On the contrary, at high concentrations,
thrombin is able to induce cell death (63). In fact, after
exposure to high concentrations of thrombin, astrocytes become
reactive and lose their neuroprotective and supportive functions,
microglia proliferate and produce reactive oxygen species, IL-
1β, and TNFα. Moreover, high concentrations of thrombin may
produce axonal damage and retraction, intracellular calcium
upregulation, and finally cell death. Furthermore, thrombin can
induce BBB damage by digestion of extracellular matrix mediated
by MMPs (7).
Another function that thrombin has in common with
activated factor VII (FVIIa) and FXa is the activation of PARs
family proteins, expressed on the surface of several tissues
(preferentially PAR1 and PAR3 rather than PAR4 due to their
hirudin-like motif) (64) and involved in hemostasis, phlogosis,
cancer development, and embryologic differentiation (65).
There are two main thrombin inhibitors: Protease nexin 1
(PN-1) and ATIII. PN-1 is a 47 kDa serine protease inhibitor
(SERPIN) that acts as a suicide substrate for thrombin and
urokinase-type plasminogen activator (66). It represents themost
abundant and potent endogenous brain thrombin inhibitor (67).
The expression of PN-1 is high in the brain and this glycoprotein
is secreted by glial cells (68) and neurons (69). ATIII is also a
SERPIN normally expressed in the liver and at low levels in brain
tissue (70, 71). ATIII is a non-vitamin K-dependent protease that
inhibits the activity of thrombin and factors IXa and Xa. These
SERPINs have been demonstrated to be highly expressed in mice
with EAE. The expression of PN-1 in the brain of the mice with
EAE peaks at day 8 post-immunization (during the preclinical
phase), whereas ATIII peaks at day 13, when the mice experience
the highest clinical score and correlate to the disease severity (6).
Significantly higher plasma levels of both prothrombin and
factor X have been found in relapsing-remitting MS whereas
increased levels of prothrombin have been found in secondary-
progressive MS patients compared to healthy controls (9).
Conversely, no significant difference was found between controls
and patients with both primary-progressive MS and NMOSD.
Interestingly, relapse free time negatively correlated with level
of either prothrombin, factor XII, or factor X indicating
disease exacerbation as a condition characterized by increased
coagulation activity (9). Similarly, the speed of thrombin
generation was found faster in relapsing-remitting than in
primary progressive MS or healthy controls and correlated with
time from clinical diagnosis likely reflecting the differential active
proinflammatory state in eachMS subtype (72). Dermatan sulfate
and heparin inhibit the generation of thrombin activity and both
have been demonstrated to be effective therapeutic agent for EAE
(73–75).
Drugs available to block thrombin action include heparins,
hirudins (lepirudin and bivalirudin), vitamin K antagonists and a
new generation of direct thrombin inhibitors such as dabigatran
and argatroban.
FIBRINOGEN
Fibrinogen is a soluble 340-kDa glycoprotein comprised of
three distinct polypeptide chains: A-alpha, B-beta, and gamma
produced in the liver by the hepatocytes (76). Plasma
concentration of fibrinogen is 2–4 g/L, and its half-life is
about 4 days (77). Fibrinogen represents an acute-phase
reactant, therefore its plasma concentrations increase during
inflammatory response. Thrombin cleaves off fibrinopeptides
A and B from the fibrinogen molecule, exposing multiple
polymerization sites, leading to the polymerization, formation of
insoluble and stable fibrin clot and finally, with the involvement
of circulating platelets, formation of a platelet plug (78). Platelets
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bind to the C terminus of fibrinogen’s gamma-chain binds,
through their surface αIIbβ3 integrin receptor, facilitating the
formation of a platelet plug (41).
The deposition of fibrin is frequently associated with
inflammation (40) and fibrin can increase the expression of
several cytokines which, in turn, modulate cell adhesion, and
migration (79). The pattern of fibrin deposition in MS coincides
with the areas occupied by demyelinating lesions (80), and with
the areas characterized by axonal damage (81). Interestingly,
fibrin deposition may precede the formation of demyelinating
lesions (82–84).
Plasminogen and fibrinogen were found to be lower in MS
compared to healthy controls (85). These results have been
explained by a possible fibrinogen consumption and fibrin
formation due to activation of coagulation cascade leading to up-
regulation of fibrinolytic system with both increased plasmin’s
and reduced plasminogen’s levels. A recent study showed
in patients with both clinically isolated syndrome (CIS) and
relapsing-remittingMS that a high plasma fibrinogen levels had a
high specificity and specificity, but a low sensitivity for detection
of active lesions on MRI during relapses supporting a role of
fibrinogen on the development of MS lesions (86). A microarray
study has demonstrated the presence of fibrinogen transcripts
in chronic lesions of MS patients (87). Fibrinogen is able to
directly activate microglia in vitro and increase its phagocytic
ability (88). The importance of fibrinogen, especially in the early
phases of MS, has been postulated and eventually demonstrated
in mice with EAE, in which the leakage of fibrinogen from the
BBB is crucial for microglial activation (89). The deposition of
fibrin interferes with axonal regeneration (4) and pharmacologic
removal of fibrin in EAEmice has been demonstrated to suppress
disease development and improve the resulting disability (90,
91). Fibrinogen can bind to members of three major families
of integrins, beta-1 (alpha5-beta1), beta-2 (CD11b/CD18 and
CD11c/CD18), and beta-3 (alpha-v-beta3), that are expressed by
leukocytes on their surface (92).
The conversion of fibrinogen to insoluble fibrin exposes the
cryptic epitope γ377–395. This epitope in crucial for the binding
of fibrin to the integrin receptor CD11b/CD18, expressed by
microglia (41). Fibrinogen induces release of ROS in microglia
and its signaling through CD11b/CD18 is necessary for the
formation of perivascular microglial clusters and axonal damage
in EAE (89). By the activation of CD11b/CD18 pathway,
fibrinogen can stimulate the production of tissue factor (93) and
Tumor Necrosis Factor (TNF) (94) by monocytes. Furthermore,
the binding of fibrinogen to CD11b/CD18 can result in
activation of extracellular signal-regulated kinase 1/2 (ERK1/2)
or the phosphoinositide-3 kinase (PI3K) pathway, important for
neutrophil survival (95). Nuclear factor kappa B (NF-kappaB)
pathway is also activated by fibrinogen and results in increased
production of IL-1alpha in monocytes (96).
Mice with EAE, treated with pharmacological depletion of
fibrinogen showed a direct reduction of microglia activation
(88, 97). An interesting transgenic mouse model (Fib-
gamma390−396A), characterized by the suppression of the
interaction of fibrinogen with CD11b/CD18 was studied in
order to analyse the exact role of fibrinogen in EAE. The
Fib-gamma390−396A mice with EAE had better clinical scores,
decreased inflammation, increased survival rate, and improved
motor function than laboratory controls.
A new generation of inhibitors of the coagulation pathway,
for example inhibiting fibrinogen binding to CD11b/CD18, with
decreased haemorrhagic side effects have been proposed as future
treatments of chronic inflammatory diseases, including MS (15,
41). Recently, fibrin-targeting immunotherapy with monoclonal
antibody 5B8, targeted against the cryptic fibrin epitope
γ377−395, has been demonstrated to inhibit autoimmunity-
and amyloid-driven neurotoxicity without globally suppressing




Several studies have documented presence of products of the
fibrinolytic system in MS. Plasminogen is a 93-kDa single chain
glycoprotein with an average plasma concentration of 0.2 mg/mL
(98). Tissue plasminogen activator (tPA) is a 69-kDa glycoprotein
consisting of 527 or 530 amino acids, released as a single chain
enzyme, with an average plasma concentration of 5–10 ng/mL
(98, 99). Urokinase plasminogen activator (uPA) exists in two
forms with different molecular weight: high molecular weight
uPA [54 kD], and low molecular weight uPA [33 kD], with a
plasma concentration of 1 ng/mL (98). The binding of uPA to its
receptor (uPAR) is crucial for the activation of plasminogen to
plasmin (100). Leukocytes constitutively express uPAR and the
presence of soluble forms of uPAR has been associated with BBB
disruption in neurological diseases (101).
Both tPA and uPA convert plasminogen to plasmin and,
through a positive feedback mechanism, plasmin cleaves both
tPA and uPA, transforming them from their single chain forms
to the more active double-chain forms (102). Fibrin represents
the major plasmin substrate and enhances plasmin generation by
binding both plasminogen and tPA on its surface, increasing also
the affinity between tPA and plasminogen (102). Plasmin cleaves
fibrin, generating soluble degradation products.
Samples of CSF from MS patients have increased tPA activity
as compared to control subjects and the increase in tPA activity
correlates with the disease progression (103, 104). In mice
with EAE, tPA is detected in macrophages of inflammatory
cuffs in the spinal cord (105), and tPA mRNA and protein
expression are upregulated, also in neurons (106, 107). Moreover,
it has been shown that in MS and in EAE, the uPA, and tPA
mediated activation of ubiquitous plasminogen represents a key
step in the activation cascade of the four classes of matrix
MMPs: collagenases, stromelysins, membrane-type MMPs, and
gelatinases. MMPs contribute to the extravasation of circulating
lymphocytes and monocytes, by modifying matrix components
and can generate encephalitogenic peptides from myelin basic
protein (107).
Neurons and microglia in the CNS express tPA (108) and
it has been shown that tPA has also an interesting function in
neural plasticity. In fact, tPA system has a significant role also
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in brain tissue remodeling and cell migration (109, 110). tPA
is secreted during axonal growth and regeneration, facilitating
nerve outgrowth through a tissue matrix (111). tPA levels are
reduced in mature brain, with highest levels found in the
dentate gyrus and cerebellum (112). tPA mRNA expression is
enhanced during cerebellar motor learning tasks in rats and this
is considered as a mechanism of synaptic plasticity (113).
In contrast with the increased tPA activity in the CSF from
MS patients, tPA deficient mice experienced an early and a more
severe and acute EAE as compared to wild-type controls. On the
contrary, uPAR deficient mice experienced a delayed and less
acute EAE, with a delayed but steadily increased infiltration of
inflammatory cells (114). These data highlight the complex role
of tPA and uPAR in the pathogenesis of EAE by regulating fibrin
deposition at sites of inflammation and cell trafficking into the
CNS (114).
Protein C is a vitamin K-dependent zymogen of a serine
protease. Protein C is activated by thrombin when both bind
to endothelial cell TM. The endothelial protein C receptor
(EPCR) also binds protein C. Activated protein C (APC) is a
natural anticoagulant. With its cell membrane localizing cofactor,
protein S (PS), APC binds to endothelium and activated platelet
membranes and intervenes in degradation of procoagulant factor
Va and VIIIa, consequently limiting further thrombin formation
(115). Impaired TM-dependent aPC generation aggravates
EAE disturbing myelination and mitochondrial function and
increasing mitochondrial ROS (116). Soluble TM ameliorates
EAE and dampened demyelination in the cuprizone-diet model.
Recombinant TM ameliorated the clinical and pathological
severity of EAE by suppressing plasma levels of inflammatory
cytokines (117). Protein C deficiency can be inherited or acquired
and causes an important predisposition to thrombosis. However,
the roles of APC are not limited to coagulation. APC helps
maintain endothelial cell integrity (118), inhibits leukocyte
adhesion and BBB crossing (119), reduces the production of
pro-inflammatory cytokines (118, 120–123) and has anti-oxidant
properties (124). EPCR has structural similarities with the
MHC1/CD1 family of molecules, suggesting further possible
roles of the protein C pathway in regulating the immune
response (118, 125).
Protein C activity was found reduced in MS patients
independently from their lupus-anticoagulant activity or factor
Va resistance (126). The role of APC in MS has become matter of
debate (125).
ANTIPHOSPHOLIPID ANTIBODIES
In common clinical practice serum reactivity for
antiphospholipid antibodies (APLs), reduction of prothrombin
time or increase of both fibrinogen and D-dimer (a product
of fibrin degradation) are accepted indicators of increased
coagulation activity, which may indicate intravascular
thrombosis. APLs have been widely studied in MS with
conflicting results, in part depending on the type of antibodies
used in the assays (127). Recently, most authors agree on a
higher APL reactivity in MS than in healthy controls even if
it is variable according to different disease forms and phases
(127–130). APL positivity in MS patients is associated with a
more severe clinical and MRI disease progression supporting
the concept that the degree of involvement of coagulation in
inflammatory-demyelinating diseases is proportional to disease
severity (127, 131). Increased APL reactivity has been found
in both relapsing-remitting and secondary-progressive MS
compared to healthy controls with the highest APL positive
rate (> 50%) during the clinical exacerbations and with its
decrease a few months after relapse (132). Interestingly, among
a broad different APLs only anti-prothrombin and anti-β2
glycoprotein-I antibodies were independently higher in relapse
compared to both remission and secondary progressive phase
(132). Furthermore, as an example of the close correlation
between neurodegenerative and thrombogenic mechanisms
in MS, it was showed that high total and LDL levels of
cholesterol in MS patients were significantly associated with both
disease duration and disability as well as with anti-annexin V
positivity (133). Since hydroxychloroquine, a drug with anti-
infective, anti-inflammatory and anti-thrombotic properties,
protects the annexin V anticoagulant shield from disruption
by antiphospholipid antibodies on phospholipid bilayers (134),
annexin V has been proposed as a new attractive therapeutic
target in MS (135). Ongoing clinical trials are currently
testing the effect of hydroxychloroquine in slowing down the
progression of clinical disability in MS (ClinicalTrials.gov
identifiers NCT02913157 and NCT03109288).
ALTERATION OF THE COAGULATION
PATHWAY IN NEUROMYELITIS OPTICA
SPECTRUM DISORDERS
Neuromyelitis optica spectrum disorders (NMOSD) represent
a more severe CNS inflammatory-demyelinating disorder than
MS, characterized by optic neuritis, longitudinally extensive
myelitis, and water channel aquaporin-4 autoantibody positivity
(136). There are only a few studies comparing coagulation
markers including APLs and thrombotic events between MS
and NMOSD. A higher anticardiolipin positive rate was found
in NMOSD compared to MS patients, associated with a
greater ATIII activity and D-dimer level (137). Farber and co-
authors reported a significantly higher association of venous
thromboembolism with NMOSD than with MS, within 6 weeks
of acute relapse, after its correction for influencing factors such as
age, length of stay and ambulatory disability (138). These findings
are not surprising since a coagulation activation is greater in
so far as there is a more severe disease. Partially common
pathogenetic mechanisms mediated by coagulation factors and
complement, which are part of innate immunity and activate the
adaptive immunity, have been supposed for both inflammatory-
demyelinating and thrombotic (e.g., antiphospholipid syndrome)
CNS diseases (139).
In a recent study investigating the coagulation status of
NMO and MS patients, Zhang and colleagues demonstrated
that fibrinogen levels were significantly higher in NMO
and MS patients compared to non-inflammatory neurological
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disease subjects as a control group and that there was no
difference between MS and NMO. Moreover, fibrinogen levels
were significantly associated with the severity of the disease
(19). In another study, Göbel and colleagues showed that
fibrinogen level was significantly lower in NMOSD compared to
both relapsing-remitting and secondary-progressive MS, albeit
NMOSD patient’s number was low (10). Undoubtedly, peripheral
blood measurement of coagulation factors in organ-specific
diseases such as MS and NMOSD has some limitations, however




Although there is only a few histopathological examinations of
MS samples from the acute phase of the disease (140–143), they
have shown early microglia activation (pre-demyelinating lesion
stage) after fibrinogen leakage through the damaged BBB (143),
as well as the presence of some clotting factors in chronic active
lesions identified by a proteomic approach (144).
Moreover, quantitative contrast-enhanced MRI studies found
a low grade of BBB leakage in visibly non-enhancing MS
lesions, distinct from a significantly greater BBB damage in
visibly enhancing lesions (145). The authors showed that
this low grade BBB leakage was not influenced by ongoing
immunomodulatory therapies supposing a permanent structural
changes of vessel walls in chronic long-standing lesions.
The abnormalities in “tight” junctions (TJ) between adjacent
endothelial cells, which are part of BBB, were found even
in normal-appearing white matter (NAWM) (146). The TJ
abnormality was not confined to microvasculature but involved
the full range of vessels either in MS lesions or in NAWM
by a possible effect of pro-inflammatory soluble mediators
such as cytokines acting “a distance” (147). The association of
fibrinogen leakage with astrocyte’s processes as well as with TJ
abnormality was most pronounced in active lesions. Also ex vivo
pathological-imaging correlations using magnetization-transfer
ratio and diffusion-tensor imaging showed subtle abnormalities
in NAWM, closes to MS lesions and correlated with diffuse
microglia activation along with impaired axonal and myelin
integrity (148). Furthermore, dynamic-susceptibility enhanced
T2∗-weighted MRI demonstrated prolonged brain blood mean
transit time and decreased cerebral blood flow in both white and
gray normal-appearingmatter of relapsing-remittingMS patients
as well as in NAWMof patients with CIS suggesting a continuum
of tissue perfusion slowdown starting from white matter and
spreading to gray matter (149).
Similarly, histological studies in chronic MS have showed a
small deposition of extravascular fibrin in chronic, non-activeMS
lesions suggesting a persistent BBB damage (82). This steady BBB
dysfunction, likely due to its permanent reparative thickening,
could determine a continuous low outflow of soluble mediators
and inflammatory cells from blood to CNS. Inflammation
in progressive MS occurs in the form of compartmentalized
immune reaction behind a closed/repaired BBB leading to a
formation of lymph-follicle like structures in the meninges
and perivascular spaces (150). These local structures produce
cytokines, chemokines, and intrathecal immunoglobulins leading
to brain damage and disease progression. Compartmentalized
inflammation could in part explain the incongruity between
greater brain atrophy and fewer radiological inflammatory
lesions in progressive MS.
Based on these observations, we could speculate that “soluble”
clotting factors and pro-inflammatory mediators released from
platelet’s granules may in part mediated MS pathogenesis by
innate immune activation and consequent adaptive immune
stimulation. They pass persistently and subtly in the CNS due to
a long-lasting BBB dysfunction in the course of the disease, and
more strikingly during MS relapses through acute BBB damage.
The big question remains: what triggers these processes and why
they occur only in a subgroup of people?
In the health, CNS “immune privilege” status is determined by
BBB integrity together with neurons, glia, and the extracellular
matrix, which form the neurovascular unit regulating immune
responses in the CNS (151). Cell-contact signals expressed by
neurons and glia (as a result of neuronal cell adhesion molecules)
inhibit both microglia activation and maturation of antigen-
presenting cells. Additionally, neurons produce chemokines,
neuropeptides, neurotransmitters, and neurotrophins acting
as neuroimmunoregulatory mediators to inhibit microglia
activation and limit the survival of activated lymphocytes.
The impairment of these cell-contact signals due to neuronal
damage depletes CNS homeostatic protective environment
increasing neuroinflammation (151). This occurs physiologically
in aging due to neuronal loss, genetic mutations, oxidative, or
metabolic stress with endoplasmic reticulum and mitochondrial
dysfunction.
Neurodegeneration seems to be closely associated with
neuroinflammation not only in MS, but also in other
neurodegenerative disorders due to a chronic activation of
the local innate immunity, and in particular of microglia.
Microglia is involved in defense against CNS infections and
in cleaning of cell debris and damaged proteins, however, its
excessive or prolonged activation may cause tissue damage (151).
Furthermore, local innate immune activation largely determines
adaptive immune response. In fact, neuroinflammation
manifests not only with activation of local microglia, astrocytes,
oligodendrocytes but also with a recruitment of peripheral
innate immune cells such as natural killer, natural killer T cells,
mast cells, granulocytes and γδ-T cells as well as of circulating
lymphocytes and myeloid cells from the periphery. Activated
microglia, by secreting Il-1α, TNF and C1q, induce reactive A1
astrocytes that induce the death of neurons and oligodendrocytes
due to their lost ability to promote neuronal survival, outgrowth,
synaptogenesis and phagocytosis in neurodegenerative disorders
(152). Mutually, systemic immune activation influences the
local innate immunity. Peripheral ongoing and precedent
infections determine the so-called “primed” environment that
increases CNS susceptibility to injury. Experimental studies
showed that peripheral inflammation is associated with disease
exacerbations in experimental models of either MS, stroke or
other neurodegenerative diseases (151).
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The same mediators and cells that are involved in
neuroinflammation and neurodegeneration, have provide
for CNS repair, growth and development (151). Astrocytes
are the major source in the CNS of nerve growth factor
and glial cell line-derived neurotrophic factor, which are
secreted also by T cells. Microglia/macrophages release growth
factors and cytochines stimulating axonal regeneration and
oligodendrocyte-precursors maturation. However, as in other
neurodegenerative diseases, in MS spontaneous regeneration or
self-repair of damaged CNS tissue is inadequate compared to
the extent of neuroinflammation and neurodegeneration, which
co-exist in different degree depending on many factors including
tissue localization, lesion formation stage, disease phase and
immune system age (153). In acute and limited CNS injury,
neuroinflammation could circumscribe neurodegeneration and
stimulate regeneration. Conversely, chronic neuroinflammation
leads to increased neurodegeneration that in turn impairs
homeostatic protective environment further amplifying
neuroinflammation and weakening regeneration.
Recurrent or chronic infections lead to immunothrombosis,
which is activated by blood-borne pathogens and circulating
damaged self-components (46), and are presumably among the
causes of chronic neuroinflammation. There is a continuous
crosstalk between the immune system and blood coagulation
components, closely inter-correlated, and essential for an
effective immune response to limit pathogen dissemination and
support pathogen killing and tissue repair (45). However, over-
activation of coagulation may induce thrombotic complication,
excessive inflammation, and tissue damage. Infections cause the
modification of proteins’ structure and function by increased
oxidative stress. A progressive trend of oxidation of several serum
proteins including coagulation factors from remission to relapse
was found in relapsing-remitting MS patients (154). Moreover,
a possible role of transient virus-BBB interactions during viral
infections triggering focal inflammation, BBB breakdown and
demyelination in some cases of MS has been previously supposed
(155). The study of gene-environment interactions showed the
relevant relationship between MS genotype and Epstein Barr
virus, however also other viruses may perturb the human
molecular system by common and unique virus strategies (156).
A Danish nationwide nested case-control study found that
children with MS have more infections in the 3 years preceding
MS beginning that is influenced also by their immune response
to infections (157). It is known that several micro-organisms play
a role in MS relapse and pathogenesis. Additionally, a recent
review based on Cochrane library guidelines concluded that
somemicro-organisms such as Human herpesvirus 6, Chlamydia
pneumoniae and Torque teno virus have contributed to making
MS a chronic progressive disease, but it does not rule out the
role of other pathogens in MS progression (158). Finally, by
immunohistochemistry using specific antifungal antibodies, the
microfoci of fungal structures in CNS tissue sections, which was
also positive for bacteria, were observed in MS patients but not
in controls supporting the polymicrobial infections as a possible
cause of MS (159).
CONCLUSIONS
In addition to histopathological observations on early microglia
and astrocyte activation after fibrinogen leakage through
the damaged BBB in MS and EAE, many observational
and experimental studies in MS and NMOSD showed their
association either with pro-thrombotic risk factors, increased
prevalence of thrombotic and vascular diseases or involvement
of clotting factors as well as of complement and platelets, other
components of coagulation cascade.
Taken all together, there is evidence for a role of coagulation
in the pathogenesis of bothMS and NMOSD. It will be important
to better define the exact links between immune response
and coagulation pathways dysregulation. The new challenge
ahead will be to understand how this interaction converges on
recently described mechanisms of neurodegeneration induced by
activated microglia and reactive astrocytes. This approach may
lead to improved treatment options (e.g., polytherapies), not only
for demyelinating diseases but also for other neurodegenerative
conditions.
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